General Information of Drug Inactive Ingredient (DIG) (ID: E00436)

DIG Name
Colcothar yellow
Synonyms
Iron(III) oxide; Umber; oxo(oxoferriooxy)iron; Iron trioxide; Iron oxide fume; MFCD00011008; Iron(III)oxidemono hydrate; Iron(III) oxide, dispersion; Eisen(III)-oxid; Iron(III) Oxide Nanoparticles / Nanopowder; Eisentrioxid; iron-oxide; Zelaza tlenki; Iron oxide, red; Red Ferric Oxide; Iron Oxide Yellow; iron(3+) oxide; Iron Oxide Nanopowder; Iron Oxide Nano Rods; Anhydrous Ferric Oxide; Iron Oxide Pigment Red; Nano Iron Oxide Powder; Zelaza tlenki [Polish]; Ferrous Oxide Nanopowder; Iron oxide (Fe203); Iron oxide fume, as Fe; Fe2O3; Iron(III) Oxide Nanowires; Iron(III) oxide, 99%; Anhydrous Iron (III) Oxide; Iron trioxide, dust and fume; NIOSH/NO7525000; CHEBI:50819; Ferric Oxide (Alpha) Nanopowder; Ferric Oxide (Gamma) Nanopowder; Iron oxide dust and fume (as Fe); Iron(III) oxide, red (Hematite); 8651AF; AKOS015904091; Iron(III) oxide, cosmetic, NanoArc?; Iron(III) oxide, magnetic, NanoArc?; Iron(III) oxide, purified, >=95%; DB11576; Iron(III) oxide (99.995%-Fe); Iron(III) oxide, industrial, NanoArc?; Iron Oxide DEAE Core Shell Nanoparticles; FT-0695872; NO75250000; Iron(III) oxide, powder, <5 mum, >=99%; Iron(III) oxide, 99.98% trace metals basis; Iron(III) oxide, SAJ first grade, >=98.0%; Iron(III) oxide, >=99.995% trace metals basis; Iron(III) oxide, Vetec(TM) reagent grade, 95%; Iron oxide nanoparticles in water, 10nm, with PEG; Iron oxide nanoparticles in water, 20nm, with PEG; Iron oxide nanoparticles in water, 30nm, with PEG; J-005905; Iron Oxide Silicon Dioxide Titanium Oxide Core Shell; Iron Cobalt Niobium (Fe-Co-Nb) Alloy Sputtering Targets; Iron(III) oxide, puriss., >=97.0% (complexometric); Iron(III) oxide, nanopowder, <50 nm particle size (BET); Iron(III) oxide, pieces, 3-12 mm, 99.8% trace metals basis; Iron oxide nanoparticles, 10nm, organic solvent-dispersible (in chloroform); Iron oxide nanoparticles, 20nm, organic solvent-dispersible (in chloroform); Iron oxide nanoparticles, 30nm, organic solvent-dispersible (in chloroform); Iron oxide nanoparticles in water, 10nm, with amine surface functional group; Iron oxide nanoparticles in water, 10nm, with carboxylic acid surface functional group; Iron oxide nanoparticles in water, 20nm, with amine surface functional group; Iron oxide nanoparticles in water, 20nm, with carboxylic acid surface functional group; Iron oxide nanoparticles in water, 30nm, with amine surface functional group; Iron oxide nanoparticles in water, 30nm, with carboxylic acid surface functional group; Iron(III) oxide, dispersion, nanoparticles, <=110 nm particle size, 15 wt. % in ethanol; Iron(III) oxide, dispersion, nanoparticles, <=110 nm particle size, 20 wt. % in H2O
DIG Function
Colorant
Formula
Fe2O3
Canonical SMILES
O=[Fe]O[Fe]=O
InChI
1S/2Fe.3O
InChIKey
JEIPFZHSYJVQDO-UHFFFAOYSA-N
Physicochemical Properties Molecular Weight 159.69 Topological Polar Surface Area 43.4
XlogP N.A. Complexity 34.2
Heavy Atom Count 5 Rotatable Bond Count 0
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 3

Full List of Drug(s) Co-administrated with This DIG

23 Approved Drug(s) Co-administrated with This DIG
Drug Name Drug ID Indication Formulation Name Formulation ID
Cariprazine DMJYDVK Bipolar disorder [6A60] Cariprazine Hydrochloride eq 3mg base capsule F23398
Cyclobenzaprine DM1YBRM Depression [6A70-6A7Z] Cyclobenzaprine Hydrochloride 10mg tablet F23408
Dapagliflozin DM28UJG Type-2 diabetes [5A11] Dapagliflozin Propanediol 5mg tablet F23957
Fenoprofen DML5VQ0 Rheumatoid arthritis [FA20] Fenoprofen Calcium eq 200mg base capsule F23448
Fexofenadine DM17ONX Allergic rhinitis [CA08.0] Fexofenadine Hydrochloride 180mg tablet F23449
Fluvastatin DM4MDJY Hypercholesterolaemia [5C80.0] Fluvastatin Sodium eq 80mg base extended release tablet F23459
Ibrutinib DMHZCPO Mantle cell lymphoma [2A85.5] Ibrutinib 140mg tablet F23773
Ivabradine DM0L594 Angina pectoris [BA40] Ivabradine Hydrochloride eq 5mg base tablet F23963
Lonafarnib DMGM2Z6 Hutchinson-Gilford progeria syndrome [LD2B] Lonafarnib 50 mg capsule F24392
Lorcaserin DMG6OYJ Obesity [5B81] Lorcaserin Hydrochloride 20mg tablet F23473
Nilotinib DM7HXWT Chronic myelogenous leukaemia [2A20.0] Nilotinib Hydrochloride Monohydrate eq 50mg base capsule F23493
Ozanimod DMT6AM2 Multiple sclerosis [8A40] Ozanimod 0.23 mg capsule F24103
Panobinostat DM58WKG Multiple myeloma [2A83] Panobinostat Lactate eq 10mg base capsule F23503
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour [2F7B] Pexidartinib 200 mg capsule F23256
Pimavanserin DMR7IVC Parkinson disease [8A00.0] Pimavanserin Tartrate 10 mg tablet F23516
R0-93877 DMM4U9G Constipation [DD91.1] Prucalopride 2 mg tablet F23875
Ranitidine DM0GUSX Peptic ulcer [DA61] Ranitidine Hydrochloride eq 150 mg base tablet F23534
Rucaparib DM9PVX8 Ovarian cancer [2C73] Rucaparib Camsylate eq 300mg base tablet F23543
Saquinavir DMG814N Human immunodeficiency virus infection [1C62] Saquinavir Mesylate eq 200mg base capsule F23546
Silodosin DMJSBT6 Benign prostatic hyperplasia [GA90] Silodosin 8mg capsule F23893
Talazoparib DM1KS78 Breast cancer [2C60-2C65] Talazoparib 0.25 mg capsule F24298
Tofacitinib DMBS370 Rheumatoid arthritis [FA20] Tofacitinib Citrate eq 22mg base extended release tablet F23570
Voxelotor DMCS6M5 Sickle-cell disorder [3A51] Voxelotor 500 mg tablet F23323
------------------
⏷ Show the Full List of 23 Approved Drug(s)